Hope Rugo retweeted
Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials
ascopubs.org/doi/full/10.12…
ascopubs.org/doi/full/10.12…
0
14
37
3,420
Exciting to see so many presentations in print on the day of presentation. For the first time ever - 6 papers in @ESMO_Open. Congratulations to the authors and thanks to @Esmo, our editors, and Elsevier for helping this happen!
Concomitant publications at #ESMO26: new data moving swiftly from the podium to the peer-reviewed journals.
@Annals_Oncology @ESMO_Open @NEJM @NatureMedicine @TheLancet @TheLancetOncol @Nature @JAMA_current
3
15
42
2,917
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer globenewswire.com/news-release/2…
0
10
23
1,900
#ESMO26 @PTarantinoMD presents the novel and unique Charisma trial with matched samples starting an ADC then with PD. My take? Resistance is incredibly complex and not due to an isolated pathway. Down reg of receptor target uncommon. @OncoAlert
2
14
30
1,587
#ESMO26 ctDNA response predicted long disease control in mHER2+ disease published today in the open access @ESMO_Open could direct stopping therapy earlier in a subset. STOPHER2 ongoing. @OncoAlert
0
12
20
4,321
#ESMO26 nice summary by Antonio Llombart on CNS studies in mHER2 positive disease! Congrats to all. @OncoAlert
0
21
33
1,681
#ESMO2026 2 interesting presentations on HER2 isolated brain Mets and LMD. Tucatinib HP for brain Mets and IT HP for LMD. Remarkable efficacy for both! Impact on clinical practice. @OncoAlert
2
15
39
2,890
Very exciting to have Bridget published simultaneously in @ESMO_Open available open access on line!! @drsarahsam @laura_huppert @PTarantinoMD @OncoAlert
0
10
15
737
AND high efficacy of TDXd/P in DB09 - big progress that can potentially lead to prevention!@drsarahsam (can’t find the other handles!) @OncoAlert
#ESMO2026 2 interesting presentations on HER2 isolated brain Mets and LMD. Tucatinib HP for brain Mets and IT HP for LMD. Remarkable efficacy for both! Impact on clinical practice. @OncoAlert
0
9
16
1,224
#ESMO2026 Meng presents phase 2 data with a nectin4 vedotin ADC bulumtatug fuvedotin. Heavily pretreated TNBC. Most with prior ADC. Ongoing trial in US and EU. Exciting new approach. @OncoAlert
0
9
12
694
#ESMO2026 wang presents first data with an effective B7H3 topo 1 ADC. Patients had not received a prior ADC. Expression did not predict response. @OncoAlert
0
9
11
804
#ESMO2026 Lei Fan presents a small prospective ADC switching trial largely post topo1 ADCs. Low response and PFS in general. Fast PD on 1st line predicted better ORR on next ADC. New payloads urgently needed. @OncoAlert
0
13
22
1,044
#ESMO2026 @RitaNandaMD beautiful and balanced discussion of 2nd set of BC abstracts today. Highlighting her summaries below.
1
19
40
2,198
Binghe Xu presents data from the Healer trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and modest increase in heme tox. Lipo doce approved in US. Today Publ in NEJM! #ESMO2026 @OncoAlert
1
10
18
1,528
Hope Rugo retweeted
📢 #ESMO26 concomitant paper - Atirmociclib and fulvestrant for patients with HR+/HER2– advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
🔗tinyurl.com/449n4nu2
@hoperugo
🔗tinyurl.com/449n4nu2
@hoperugo
0
5
13
1,508
@antgiorda beautifully presents our data from Fourlight 1 with the CDK4i atirmociclib/fulv vs fulv or eve/exe as 2nd line Rx for HR+ MBC. At 13.7 mo med FU, n=263, 38%esr1m, 40% PIKm, PFS 9.4 v 6.6mo HR 0.6 p0.007. Beautiful data. Await Fourlight 3 1st line study! @OncoAlert
2
9
26
1,350
